MAINZ, Germany - BioNTech SE (NASDAQ:BNTX), a biopharmaceutical company, announced the appointment of Annemarie Hanekamp as Chief Commercial Officer, effective July 1, 2024. Hanekamp will be succeeding Sean Marett and is transitioning from her role at Novartis AG (SIX:NOVN). She is tasked with driving BioNTech's global commercialization strategy, particularly as the company prepares for its first oncology product launch slated for 2026.
Hanekamp brings over two decades of healthcare industry experience, with a focus on commercial strategy for oncology products. Her expertise spans sales, marketing, and market access. At Novartis, she played a pivotal role in the successful launch of a novel prostate cancer treatment and was instrumental in establishing a new global oncology organization.
BioNTech's Supervisory Board Chairman, Helmut Jeggle, praised Hanekamp's extensive experience with over a dozen successful product launches, including first-time launches in the solid tumor space, which aligns with BioNTech's focus areas such as lung, breast, and prostate cancer. Jeggle expressed confidence in Hanekamp's ability to lead BioNTech's transformation into a multi-product company.
Hanekamp expressed her belief in the potential of BioNTech's pipeline and its vision to improve cancer treatment outcomes. She emphasized her commitment to bringing innovative therapies to market and creating value for patients, society, and shareholders.
BioNTech, known for its mRNA vaccine technology, has a broad portfolio of oncology product candidates and plans to seek approval for ten potential indications by 2030. The company has established partnerships with several pharmaceutical entities to advance its research and development efforts.
The information in this article is based on a press release statement from BioNTech SE.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.